Author Affiliation: Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, Atlanta, Ga.
With near elimination of Haemophilus influenzae
type b (Hib) disease through use of conjugate vaccines in many countries and
newly available pneumococcal conjugates, prevention of meningococcal disease
is an increasingly important priority for control of bacterial meningitis.
The elegant meningococcal vaccine immunogenicity study by MacLennan and colleagues1 in this issue of THE JOURNAL is another example of
how polysaccharide protein conjugation can overcome the immunologic shortcomings
of plain polysaccharide vaccines in infants and young children.
Perkins BA. New Opportunities for Prevention of Meningococcal Disease. JAMA. 2000;283(21):2842-2844. doi:10.1001/jama.283.21.2842